PL331465A1 - Novel compounds and agents for treating diseases associated with triptase activity - Google Patents
Novel compounds and agents for treating diseases associated with triptase activityInfo
- Publication number
- PL331465A1 PL331465A1 PL97331465A PL33146597A PL331465A1 PL 331465 A1 PL331465 A1 PL 331465A1 PL 97331465 A PL97331465 A PL 97331465A PL 33146597 A PL33146597 A PL 33146597A PL 331465 A1 PL331465 A1 PL 331465A1
- Authority
- PL
- Poland
- Prior art keywords
- triptase
- agents
- activity
- novel compounds
- diseases associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL331465A1 true PL331465A1 (en) | 1999-07-19 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL97331465A PL331465A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and agents for treating diseases associated with triptase activity |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (hu) |
| JP (1) | JP2001509787A (hu) |
| KR (1) | KR20000029679A (hu) |
| CN (1) | CN1073103C (hu) |
| AU (1) | AU733621B2 (hu) |
| CA (1) | CA2262542A1 (hu) |
| CZ (1) | CZ29799A3 (hu) |
| EE (1) | EE9900036A (hu) |
| FI (1) | FI990171A (hu) |
| HU (1) | HUP0003267A3 (hu) |
| LV (1) | LV12291B (hu) |
| NO (1) | NO990433L (hu) |
| NZ (1) | NZ333713A (hu) |
| PL (1) | PL331465A1 (hu) |
| SI (1) | SI9720047A (hu) |
| SK (1) | SK8599A3 (hu) |
| WO (1) | WO1998004537A1 (hu) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| WO1999040073A2 (de) * | 1998-02-06 | 1999-08-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase-inhibitoren |
| US6489327B1 (en) * | 1998-02-06 | 2002-12-03 | Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. | Tryptase inhibitors |
| EP1115731A2 (de) * | 1998-09-04 | 2001-07-18 | Byk Gulden Lomberg Chemische Fabrik GmbH | Neue pyranosen |
| US6673786B1 (en) | 1999-08-10 | 2004-01-06 | Altana Pharma Ag | Tryptase inhibitors |
| AU778965B2 (en) * | 1999-09-14 | 2004-12-23 | Altana Pharma Ag | Tryptase inhibitors |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (de) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DK1244614T3 (da) | 1999-12-20 | 2004-09-27 | Altana Pharma Ag | Tryptase-inhibitorer |
| TR200402322T4 (tr) * | 1999-12-20 | 2004-12-21 | Altana Pharma Ag | Triptaz inhibitörler |
| US6924305B2 (en) | 2001-01-31 | 2005-08-02 | Altana Pharma Ag | Diazocine derivatives and their use as tryptase inhibitors |
| EP1363874B1 (en) * | 2001-02-21 | 2007-06-06 | ALTANA Pharma AG | Tryptase inhibitors |
| EP1368317B1 (en) | 2001-02-21 | 2006-12-27 | Altana Pharma AG | Tryptase inhibitors |
| AU2002254941B2 (en) * | 2001-03-15 | 2007-05-17 | Altana Pharma Ag | Tryptase-inhibitors |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE380029T1 (de) | 2001-06-11 | 2007-12-15 | Xenoport Inc | Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2002102771A1 (en) | 2001-06-19 | 2002-12-27 | Altana Pharma Ag | Tryptase inhibitors |
| NZ554737A (en) | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
| EP2373304B1 (en) | 2008-12-19 | 2014-07-30 | Merz Pharma GmbH & Co. KGaA | Neramexane for the treatment of mast cell mediated diseases |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| FR3038605B1 (fr) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
| AU2018266393A1 (en) * | 2017-05-12 | 2019-12-19 | Riken | Class A GPCR-binding compound modifier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| NZ263084A (en) * | 1993-03-12 | 1997-08-22 | Arris Pharm Corp | Dipeptide derivatives, treatment of immunomediated inflammatory disorders |
| EP0688337A1 (en) * | 1993-03-12 | 1995-12-27 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| US5656660A (en) * | 1994-06-01 | 1997-08-12 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
| WO1996009297A1 (en) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell inflammatory condition |
| PL322409A1 (en) * | 1995-03-24 | 1998-01-19 | Arris Pharm Corp | Reversible protease inhibitors |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 NZ NZ333713A patent/NZ333713A/xx unknown
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 EE EEP199900036A patent/EE9900036A/xx unknown
- 1997-07-30 JP JP50913698A patent/JP2001509787A/ja active Pending
- 1997-07-30 SI SI9720047A patent/SI9720047A/sl unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/ko not_active Application Discontinuation
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 CN CN97196877A patent/CN1073103C/zh not_active Expired - Fee Related
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/cs unknown
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/hu unknown
- 1997-07-30 SK SK85-99A patent/SK8599A3/sk unknown
- 1997-07-30 PL PL97331465A patent/PL331465A1/xx unknown
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/no not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/fi unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001509787A (ja) | 2001-07-24 |
| CN1226892A (zh) | 1999-08-25 |
| WO1998004537A1 (en) | 1998-02-05 |
| NZ333713A (en) | 2000-12-22 |
| CZ29799A3 (cs) | 1999-06-16 |
| NO990433L (no) | 1999-03-25 |
| AU3967097A (en) | 1998-02-20 |
| FI990171A0 (fi) | 1999-01-29 |
| NO990433D0 (no) | 1999-01-29 |
| AU733621B2 (en) | 2001-05-17 |
| LV12291B (en) | 2000-04-20 |
| EP0934293A1 (en) | 1999-08-11 |
| EE9900036A (et) | 1999-08-16 |
| SI9720047A (sl) | 1999-08-31 |
| KR20000029679A (ko) | 2000-05-25 |
| SK8599A3 (en) | 2000-03-13 |
| HUP0003267A2 (hu) | 2001-06-28 |
| CN1073103C (zh) | 2001-10-17 |
| LV12291A (lv) | 1999-06-20 |
| HUP0003267A3 (en) | 2002-02-28 |
| CA2262542A1 (en) | 1998-02-05 |
| FI990171A (fi) | 1999-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL331465A1 (en) | Novel compounds and agents for treating diseases associated with triptase activity | |
| GB9417956D0 (en) | Therapeutic agents | |
| GB9415996D0 (en) | Therapeutic agents | |
| GB9418545D0 (en) | Therapeutic agents | |
| GB9415997D0 (en) | Therapeutic agents | |
| GB9417310D0 (en) | Therapeutic agents | |
| GB9416189D0 (en) | Therapeutic agents | |
| GB9416162D0 (en) | Therapeutic agents | |
| GB9402641D0 (en) | Therapeutic agents | |
| GB9410031D0 (en) | Therapeutic agents | |
| EP0921803A4 (en) | METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES | |
| GB9411955D0 (en) | Therapeutic agents | |
| GB9415575D0 (en) | Therapeutic agents | |
| GB9409264D0 (en) | Therapeutic agents | |
| GB9401879D0 (en) | Therapeutic agents | |
| GB9403639D0 (en) | Therapeutic agents | |
| LT99019A (en) | Novel compounds and compositions for treating diseases associated with tryptase activity | |
| GB9416428D0 (en) | Therapeutic agents | |
| GB9411993D0 (en) | Therapeutic agents | |
| GB9415556D0 (en) | Therapeutic agents | |
| GB9400542D0 (en) | Therapeutic agents | |
| GB9408458D0 (en) | Therapeutic agents | |
| GB9415576D0 (en) | Therapeutic agents | |
| GB9415552D0 (en) | Therapeutic agents | |
| GB9408960D0 (en) | Therapeutic agents |